PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2021-08-03

Last Posted Date: 2024-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT04987931

Locations: 🇺🇸
Pfizer Inc, New York, New York, United States

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: GBT021601

First Posted Date: 2021-07-30

Last Posted Date: 2024-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04983264

Locations: 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
Children's Healthcare of Atlanta AFLAC Center, Atlanta, Georgia, United States
🇺🇸
Visionaries Clinical Research LLC, Atlanta, Georgia, United States

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Talzenna

First Posted Date: 2021-07-29

Last Posted Date: 2024-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04982848

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Completed

Conditions: ALK-positive Non-small-cell Lung Cancer

Interventions: Drug: Lortlatinib

First Posted Date: 2021-07-28

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT04979988

Locations: 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

and more 13 locations

Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aztreonam-Avibactam

First Posted Date: 2021-07-22

Last Posted Date: 2023-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04973826

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

Phase 1

Completed

Conditions: Hypertension
Heart Failure

Interventions: Drug: Prazosin HCl 2mg
Drug: Prazosin HCl 1 mg
Drug: Prazosin HCl 5 mg

First Posted Date: 2021-07-19

Last Posted Date: 2024-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT04967443

Locations: 🇺🇸
Clinical Trials of Texas, LLC, San Antonio, Texas, United States

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participant

Interventions: Drug: Itraconazole
Drug: PF-07321332/ritonavir

First Posted Date: 2021-07-14

Last Posted Date: 2023-07-13

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04962022

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir

Phase 1

Completed

Conditions: Healthy Participant

Interventions: Drug: PF-07321332/ritonavir
Drug: Carbamazepine
Drug: PF 07321332/ritonavir

First Posted Date: 2021-07-14

Last Posted Date: 2023-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04962230

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: PF-07321332
Drug: Ritonavir

First Posted Date: 2021-07-13

Last Posted Date: 2023-02-09

Lead Sponsor: Pfizer

Target Recruit Count: 2246

Registration Number: NCT04960202

Locations: 🇺🇸
Cahaba Research Inc, Pelham, Alabama, United States
🇺🇸
The Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States
🇺🇸
Hope Clinical Research, Canoga Park, California, United States

and more 196 locations

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

Recruiting

Conditions: Metastatic Breast Cancer

First Posted Date: 2021-06-24

Last Posted Date: 2023-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 350

Registration Number: NCT04937660

Locations: 🇪🇬
Dar El Salam Oncology Hospital, Cairo, Egypt
🇪🇬
National Cancer Institute, Cairo, Egypt
🇶🇦
Hamad Medical Corporation, Doha, Qatar

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy